Search
(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide
go.drugbank.com/drugs/DB08260ExperimentalThese are compounds containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms. This drug targets the protein beta-glucosidase A. … (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide is a solid. This compound belongs to the oxepanes.
Synonyms: (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamideNorfloxacin succinil
go.drugbank.com/drugs/DB20858ExperimentalThe usage of the INN stem '-nil' in the name indicates that Norfloxacin succinil is a benzodiazepine receptor antagonist/agonist. … The usage of the INN stem '-oxacin' in the name indicates that Norfloxacin succinil is a nalidixic acid derivative antibacterial. Norfloxacin succinil has a monoisotopic molecular weight of 419.15 Da.
Tunodafil
go.drugbank.com/drugs/DB21576InvestigationalThe usage of the INN stem '-afil' in the name indicates that Tunodafil is a inhibitor of phosphodiesterase PDE5 with vasodilator action. … Tunodafil is under investigation in clinical trial NCT05976503 (A Study of the Interaction of Tunodafil Hydrochloride Tablets and Alcohol). Tunodafil has a monoisotopic molecular weight of 487.23 Da.
Tamuzimod
go.drugbank.com/drugs/DB21621InvestigationalThe usage of the INN stem '-imod' in the name indicates that Tamuzimod is a immunomodulator, both stimulant/suppressive and stimulant. … Tamuzimod is under investigation in clinical trial NCT05156125 (VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis).
PM02734
go.drugbank.com/drugs/DB05158InvestigationalPM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
ALS-08
go.drugbank.com/drugs/DB05705ExperimentalALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
LLL-3348
go.drugbank.com/drugs/DB05771ExperimentalThe botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Contulakin-G
go.drugbank.com/drugs/DB05950ExperimentalContulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.
CRA-028129
go.drugbank.com/drugs/DB05951ExperimentalCRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.